Mandate

Vinge has advised CELLINK AB (publ) in connection with its listing on Nasdaq Stockholm

Vinge has advised CELLINK AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm Main Market, with an estimated market capitalisation of approximately SEK 4.1 billion. The prospectus was published on 15 April 2020 and the trading on Nasdaq Stockholm commenced on 20 April 2020.

CELLINK is a niche life-science company developing and delivering life-science solutions for cell culturing. CELLINK focus on three application areas including bioprinting, analysis and liquid handling & bioprocessing. The target is to develop and commercialise cell culture technologies, enabling researchers to 3D-print human organs and tissues for pharmaceutical and cosmetic applications.

Vinge’s team has primarily consisted of Anders Strid, Wibeke Sorling, Edin Agic and Johanna Hamrefält (Capital Markets and Public M&A) as well as Victor Ericsson and Emelie Svanberg (Corporate Tax).

Related

Vinge advises Isofol Medical AB (publ) in connection with its rights issue of units

Through the rights issue of units, consisting of shares and warrants, and the exercised over-allotment issue, Isofol will receive approximately SEK 84 million and may receive an additional maximum of approximately SEK 110 million upon exercise of all warrants at the highest subscription price.
August 01, 2025

Vinge advises Oncorena in connection with share issue

Vinge advises Oncorena Holding AB in connection with a share issue of approximately SEK 133 million.
July 30, 2025

Vinge advises Karl Hedin and minority owners on the sale of AB Karl Hedin Sågverk to Vida

Vinge has advised Karl Hedin and minority shareholders in connection with the sale of AB Karl Hedin Sågverk to Vida Aktiebolag (“Vida”).
July 24, 2025